Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 26, 2020

Primary Completion Date

July 2, 2020

Study Completion Date

March 8, 2021

Conditions

Solid Tumor

Interventions

DRUG

Pemigatinib

Pemigatinib will be self-administered as at 13.5mg a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule.

Trial Locations (1)

Cancer Hospital of Tianjin Medical University, Tianjin

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04258527 - Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations | Biotech Hunter | Biotech Hunter